These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 30271215)
21. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer]. Zhang YF; Yu YF; Lu S Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882 [TBL] [Abstract][Full Text] [Related]
22. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial. Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156 [TBL] [Abstract][Full Text] [Related]
23. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063 [TBL] [Abstract][Full Text] [Related]
24. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. Kakutani S; Fukuhara H; Taguchi S; Nagata M; Niimi A; Hattori M; Miyazaki H; Fujimura T; Nakagawa T; Kume H; Igawa Y; Homma Y Jpn J Clin Oncol; 2015 Mar; 45(3):281-5. PubMed ID: 25425701 [TBL] [Abstract][Full Text] [Related]
25. Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. Lee HY; Shin SJ; Kim HS; Hong SJ; Han JW; Lim ST; Roh JK; Rha SY Cancer Res Treat; 2012 Mar; 44(1):43-9. PubMed ID: 22500160 [TBL] [Abstract][Full Text] [Related]
26. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118 [TBL] [Abstract][Full Text] [Related]
27. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC]. Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083 [TBL] [Abstract][Full Text] [Related]
28. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368 [TBL] [Abstract][Full Text] [Related]
29. Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma. Furubayashi N; Negishi T; Takamatsu D; Ieiri K; Inoue T; Tsukino K; Nakamura M Oncol Lett; 2020 Apr; 19(4):2943-2949. PubMed ID: 32256805 [TBL] [Abstract][Full Text] [Related]
30. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985 [TBL] [Abstract][Full Text] [Related]
31. Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study. Yamada T; Nakane K; Enomoto T; Tomioka M; Taniguchi T; Ishida T; Ozawa K; Takagi K; Ito H; Takeuchi S; Kawase M; Kawase K; Kato D; Takai M; Iinuma K; Yokoi S; Nakano M; Koie T Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140344 [TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of second-line single docetaxel (75 mg/m²) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy. Shim BY; Kim CH; Song SH; Ahn MI; Hong EJ; Kim SW; Kim S; Jo MS; Cho DG; Cho KD; Yoo J; Kim HK Cancer Res Treat; 2005 Dec; 37(6):339-43. PubMed ID: 19956369 [TBL] [Abstract][Full Text] [Related]
33. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model. Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764 [TBL] [Abstract][Full Text] [Related]
34. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014). Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419 [TBL] [Abstract][Full Text] [Related]
35. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Inal A; Kaplan MA; Kucukoner M; Isikdogan A Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282 [TBL] [Abstract][Full Text] [Related]
36. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
37. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. Baykara M; Coskun U; Berk V; Ozkan M; Kaplan MA; Benekli M; Karaca H; Inanc M; Isikdogan A; Sevinc A; Elkiran ET; Demirci U; Buyukberber S Asian Pac J Cancer Prev; 2012; 13(10):5119-24. PubMed ID: 23244121 [TBL] [Abstract][Full Text] [Related]
38. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ Oncologist; 2012; 17(1):13. PubMed ID: 22210086 [TBL] [Abstract][Full Text] [Related]
39. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Alqaisi HA; Stecca C; Veitch ZW; Riromar J; Kaiser J; Fallah-Rad N; Jiang DM; North S; Samnani S; Alimohamed N; Sridhar SS Ther Adv Med Oncol; 2022; 14():17588359221094879. PubMed ID: 35520101 [TBL] [Abstract][Full Text] [Related]
40. Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy. Mimura Y; Naiki T; Sugiyama Y; Tasaki Y; Odagiri K; Etani T; Nagai T; Iida M; Kimura Y; Ito N; Hotta Y; Yasui T; Furukawa-Hibi Y Cancer Diagn Progn; 2024; 4(4):475-481. PubMed ID: 38962546 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]